Cancer is the leading cause of mortality in China. There approximately 4.3 Million cancer cases and 2.9 Million cancer death occurred over in 2018. So an average of 7 people was diagnosed with cancer, while 4 people died of cancer every minute in China. China has 40% higher motility rate compared to the United Kingdom and the United States. Imaging tests like X-rays and CT scans assist in discovering areas of concerns, but they can’t differentiate between cancerous and noncancerous cells. For the diagnosis of cancer, a biopsy is the only sure way to identify most cancers. According to Renub Research report, China Biopsy Market is expected to reach USD 8.1 Billion by the end of the year 2026.
How COVID-19 affects China Biopsy Industry
The Coronavirus outbreak has come as a massive blow on the biopsy diagnostics centres, hospitals, supply chain and clinical trials of the biopsy industry. As per our findings, the biopsy market in China got affected a bit from December 2019 to April 2020. Read the complete analysis of COVID-19 in our report. As for how this pandemic is affecting the biopsy industry in China and when it’s going to revive.
Reasons for Growth in Cancer Cases and High Mortality Rate in China
The rise in cancer cases has been driven by an ageing population and the prevalence of lifestyle factors such as smoking, stress and sedentary lifestyle.
The prime reasons for the higher mortality in China are due to its low rate of early-stage cancers detection, and another reason is that China still has non-uniformed clinical cancer treatment strategies performed by different regions.
Top 3 Types of Cancers in China
Chinese population is mostly affected by three types of cancer Breast Cancer, Liver cancer, Colon and Rectum cancer. Breast cancer is one of the most common cancer among women in China. Our study also reveals that breast cancer rates are higher in urban areas of China than in rural areas. As with the rapid development of China’s economy, more and more people have moved from rural areas to large cities.
Request a free Brochure copy of the report: https://www.renub.com/request-sample-page.php?gturl=china-biopsy-market-p.php
This is a known fact that having more than one child lowers breast-cancer risk. But China had 1 child policy from 1979, and since most of the women work in the city, they have to follow the policy to avoid penalty. Although this one-child rule was repealed in 2015 with two-child policy rule, however, it will take 15 to 20 years for this policy to show any result.
Renub Research report titled “China Biopsy Market, by Cancer Segment (Breast cancer, prostate cancer, lung cancer, liver cancer, thyroid cancer, kidney cancer, colon & rectum cancer, kidney cancer, leukemia, pancreas cancer, and bladder cancer), Volume of Biopsy and Patient Diagnosed Numbers, Company (C. R. Bard, Inc., Becton, Dickinson and Company, Cardinal Health, Inc, Boston Scientific Corporation and Hologic, Inc.)” provides an all-encompassing analysis on the Biopsy Market in China.
10 cancer segments have been studied in this report, and each cancer segment is covered from 3 points
1. Market
2. Volume of Biopsy
3. Patient Diagnosed
Cancer Segments covered in the report
1. Breast Cancer
2. Prostate Cancer
3. Lung Cancer
4. Liver Cancer
5. Thyroid Cancer
6. Colon & Rectum Cancer
7. Kidney Cancer
8. Leukaemia
9. Pancreas Cancer
10. Bladder Cancer
All the companies have been studied from three points
• Overview
• Recent Developments
• Sales Analysis
Company Analysis
• C. R. Bard, Inc.
• Becton, Dickinson and Company
• Cardinal Health, Inc
• Boston Scientific Corporation
• Hologic, Inc.
About Company:
Renub Research is a Market Research and Consulting Company. We have more than 10 years of experience especially in international Business-to-Business Researches, Surveys and Consulting. We provide wide range of business research solutions that helps companies in making better business decisions. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. Our wide clientele comprises of major players in Life Sciences, Information Technology, Telecom, Financial Services (Banking, Insurance), Energy, Retail, Manufacturing, Automotive, and Social sector. Our clients rely on our market analysis and data to make informed knowledgeable decisions. We are regarded as one of the best providers of knowledge. Our pertinent analysis helps consultants, bankers and executives to make informed and correct decisions.
Contact Us:
Renub Research
Phone No: +1 678-302-0700 (USA) | +91-120-421-9822 (IND)
Email : info@renub.com
Fallow on Linkedin: https://www.linkedin.com/company/renub-research
Comments